MeiraGTx announces $30M strategic investment from Sanofi

MeiraGTx Holdings announced strategic updates including that Sanofi has made a $30M strategic investment in the Company through the purchase of 4.0 million ordinary shares at a price of $7.50 per share. MeiraGTx CEO Alexandria Forbes continued, “MeiraGTx is a broad-based genetic medicines company, with late-stage clinical programs, world leading end-to-end manufacturing capabilities and infrastructure, and a transformative Riboswitch gene regulation technology. As a result of the breadth of interest over the past several months from multiple parties around mutually beneficial strategic transactions involving certain assets of the Company, we have engaged Evercore and Wachtell Lipton to work with management and our Board of Directors to execute one or more of these additional potential strategic transactions and maximize value for our shareholders.”